Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
3 reports, 2 independent
Updated Sat 00:00
No new developments lately
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Also in this story
- Eli Lilly and Novo Nordisk are now competing in the basal insulin market segment.
- Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector, seeking Australian regulatory approval.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Eli Lilly and Company acquired Point and established a supply agreement with EUZ.
- Eli Lilly CEO David A. Ricks issued a company statement, coinciding with shares jumping in New York premarket trading.